{
  "turn_global_index": 446,
  "session_index": 39,
  "session_id": "577da76d_2",
  "turn_in_session": 9,
  "date": "2023/03/01 (Wed) 22:06",
  "role": "assistant",
  "content": "Risk-sharing provisions are an essential component of Advance Purchase Agreements (APAs) between the EU and vaccine manufacturers. These provisions help distribute the risks associated with vaccine development, production, and distribution between the parties involved.\n\n**What are risk-sharing provisions?**\n\nRisk-sharing provisions are contractual clauses that allocate the risks and responsibilities between the EU and the vaccine manufacturer in case of certain events or outcomes. These provisions aim to balance the risks and rewards for both parties, ensuring that the manufacturer is incentivized to develop and supply vaccines while the EU is protected from potential losses.\n\n**Types of risks shared:**\n\nThe EU and vaccine manufacturers share various risks, including:\n\n1. **Development risks:** The risk that the vaccine may not meet the required safety, efficacy, or quality standards, or that it may not be approved by regulatory authorities.\n2. **Manufacturing risks:** The risk of production delays, failures, or shortages, which can impact the supply of vaccines.\n3. **Regulatory risks:** The risk that regulatory authorities may not approve the vaccine or may impose additional requirements, affecting the vaccine's availability.\n4. **Liability risks:** The risk of adverse reactions or side effects associated with the vaccine, which can lead to legal claims and financial liabilities.\n5. **Market risks:** The risk that the vaccine may not be accepted by the market, resulting in lower-than-expected demand or sales.\n\n**How risk-sharing provisions work:**\n\nRisk-sharing provisions can take various forms, including:\n\n1. **Revenue-sharing:** The EU and the manufacturer share the revenue generated from vaccine sales, with the proportion of revenue shared depending on the level of risk.\n2. **Cost-sharing:** The EU and the manufacturer share the costs associated with vaccine development, production, and distribution, including the costs of clinical trials, manufacturing, and marketing.\n3. **Risk-based pricing:** The price of the vaccine is adjusted based on the level of risk associated with its development, production, and distribution.\n4. **Contingent payments:** The EU makes contingent payments to the manufacturer, which are conditional on the achievement of specific milestones, such as regulatory approval or sales targets.\n\n**Examples of risk-sharing provisions:**\n\nThe EU's APAs with vaccine manufacturers often include risk-sharing provisions, such as:\n\n1. **AstraZeneca:** The EU's APA with AstraZeneca includes a revenue-sharing model, where the EU pays a lower price per dose for the vaccine, and AstraZeneca absorbs some of the development and production risks.\n2. **Pfizer-BioNTech:** The EU's APA with Pfizer-BioNTech includes a cost-sharing model, where the EU and Pfizer-BioNTech share the costs of vaccine development, production, and distribution.\n\nThese risk-sharing provisions help to distribute the risks and rewards between the EU and vaccine manufacturers, ensuring that both parties are incentivized to work together to develop and supply vaccines.\n\nI hope this helps you understand the risk-sharing provisions in Advance Purchase Agreements!",
  "has_answer": false
}